

Hair Therapies Your Patients Will Be Asking About in 2026: What You Need to Know



PROGRAM OUTLINE

| 9:00AM-9:10AM | 10' | Welcome & Opening Remarks Paradi Mirmirani, MD |
|-----------------|-----|--|
| 9:10AM-9:40AM | 30' | Androgenetic Alopecia PP405 (targets mitochondrial pyruvate metabolism) – Maria Hordinsky, MD GT 20029 (topical androgen receptor degrader) – Antonella Tosti, MD |
| 9:40AM-10:10AM | 30' | Scarring Areata Brepocitinib (Tyrosine kinase 2/Janus kinase 1 inhibitor) – Maryanne Senna, MD Metformin – Crystal Aguh, MD |
| 10:10AM-10:40AM | 30' | Alopecia Areata Bempikibart (IL-7 inhibitor) – Rodrigo Pirmez, MD Amletinimab (OX-40 ligand inhibitor) – Paradi Mirmirani, MD |
| 10:40AM-10:56AM | 16' | 2025 AHRS Mentorship Grant Awardee Presentations Sofia Perez, BS (Mentor: Maryanne Senna, MD) Incidence and characteristics of frontal fibrosing alopecia and its clinical variants |
| | | Kimberly Williams, BS (Mentor: Amy McMichael, MD) Scarring alopecias and associated comorbidities in skin of color |
| 10:56AM-11:00AM | 4' | Adjourn and Closing Remarks Paradi Mirmirani, MD |